{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-033383","form_type":"8-K","ticker":"OGEN","cik":"0001174940","company_name":"ORAGENICS INC","filed_at":"2024-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.343996+00:00","generated_at":"2026-05-31T08:12:22.227111+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Oragenics completes spray-dry manufacturing of ONP-002 for Phase IIa concussion trial","bullets":["ONP-002 produced as spray-dried nanoparticle powder and filled in Oragenics' breath-propelled intranasal device.","Phase IIa trial to enroll 40 concussed patients (1:1 placebo/ONP-002), dosed twice daily for 5 days starting within 8 hours of injury in ED.","Trial will be conducted in Australia; patient-reported outcomes and blood biomarkers included in evaluation.","No approved pharmaceutical treatment for concussion; ONP-002 is a novel neurosteroid designed as first-in-class therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-033383","json":"https://secwatch.observer/filing/0001493152-24-033383.json","markdown":"https://secwatch.observer/filing/0001493152-24-033383.md","text":"https://secwatch.observer/filing/0001493152-24-033383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1174940/000149315224033383/0001493152-24-033383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1174940/000149315224033383/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:12:22.227111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}